At a glance
ClinicalIndex Comparison RecordPhase 3Completed
Drug / intervention
Montelukastdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Predicting the Bronchoprotective Response to a Leukotriene Modifier by Genetic Polymorphism
In Brief
A Phase 3 clinical trial evaluating Montelukast for Asthma. Completed, across 1 site.
Detailed Summary
The purpose of this study is to examine a specific variation in the genetic code for an enzyme (LTC4 synthase) which plays an important role in the airway inflammation associated with asthma. We hypothesize that asthmatic patients with this variant gene will have a better response to montelukast than patients with the wild type gene, as measured by the ability of montelukast to protect against a hypertonic saline challenge.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2003
First PostedJun 2005
Study CompletionDec 2006
TodayJul 2026
First PostedJun 29, 2005
Enrollment StartApr 1, 2003
Study CompletionDec 1, 2006
TodayJul 2, 2026
Posted 21.0 years ago
Interventions
Montelukastdrug